66 related articles for article (PubMed ID: 9734390)
1. Hematopoietic stem cells: are they CD34-positive or CD34-negative?
Nakauchi H
Nat Med; 1998 Sep; 4(9):1009-10. PubMed ID: 9734390
[No Abstract] [Full Text] [Related]
2. Hematopoietic capacity of preterm cord blood hematopoietic stem/progenitor cells.
Nakajima M; Ueda T; Migita M; Oue Y; Shima Y; Shimada T; Fukunaga Y
Biochem Biophys Res Commun; 2009 Nov; 389(2):290-4. PubMed ID: 19720051
[TBL] [Abstract][Full Text] [Related]
3. [Reversible expression of CD34 by hematopoietic stem cells].
Ishikawa F
Rinsho Ketsueki; 2002 Jan; 43(1):1-4. PubMed ID: 11868358
[No Abstract] [Full Text] [Related]
4. Who is hematopoietic stem cell: CD34+ or CD34-?
Pei X
Int J Hematol; 1999 Dec; 70(4):213-5. PubMed ID: 10643145
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotype and functional characteristics of human primitive CD34-negative hematopoietic stem cells: the significance of the intra-bone marrow injection.
Sonoda Y
J Autoimmun; 2008 May; 30(3):136-44. PubMed ID: 18243660
[TBL] [Abstract][Full Text] [Related]
6. Two CD34+ stem cells from umbilical cord blood enrichment methods.
Pafumi C; Bosco P; Cavallaro A; Farina M; Leonardi I; Pernicone G; Bandiera S; Russo A; Giardina P; Chiarenza M; Calogero AE
Pediatr Hematol Oncol; 2002 Jun; 19(4):239-45. PubMed ID: 12051590
[TBL] [Abstract][Full Text] [Related]
7. CD34 is a key regulator of hematopoietic stem cell trafficking to bone marrow and mast cell progenitor trafficking in the periphery.
Nielsen JS; McNagny KM
Microcirculation; 2009 Aug; 16(6):487-96. PubMed ID: 19479621
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
9. Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers.
Petersen BE; Grossbard B; Hatch H; Pi L; Deng J; Scott EW
Hepatology; 2003 Mar; 37(3):632-40. PubMed ID: 12601361
[TBL] [Abstract][Full Text] [Related]
10. A newly discovered class of human hematopoietic cells with SCID-repopulating activity.
Bhatia M; Bonnet D; Murdoch B; Gan OI; Dick JE
Nat Med; 1998 Sep; 4(9):1038-45. PubMed ID: 9734397
[TBL] [Abstract][Full Text] [Related]
11. Candidate hematopoietic stem cells from fetal tissues, umbilical cord blood vs. adult bone marrow and mobilized peripheral blood.
Huang S; Law P; Young D; Ho AD
Exp Hematol; 1998 Nov; 26(12):1162-71. PubMed ID: 9808056
[TBL] [Abstract][Full Text] [Related]
12. Reversible cell surface expression of CD38 on CD34-positive human hematopoietic repopulating cells.
McKenzie JL; Gan OI; Doedens M; Dick JE
Exp Hematol; 2007 Sep; 35(9):1429-36. PubMed ID: 17656009
[TBL] [Abstract][Full Text] [Related]
13. Evidence of peripheral blood-derived, plastic-adherent CD34(-/low) hematopoietic stem cell clones with mesenchymal stem cell characteristics.
Huss R; Lange C; Weissinger EM; Kolb HJ; Thalmeier K
Stem Cells; 2000; 18(4):252-60. PubMed ID: 10924091
[TBL] [Abstract][Full Text] [Related]
14. Cytofluorimetric analysis of CD34 cells.
Basso G; Timeus F
Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S17-20. PubMed ID: 9989883
[TBL] [Abstract][Full Text] [Related]
15. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma.
de Bont ES; Guikema JE; Scherpen F; Meeuwsen T; Kamps WA; Vellenga E; Bos NA
Cancer Res; 2001 Oct; 61(20):7654-9. PubMed ID: 11606408
[TBL] [Abstract][Full Text] [Related]
16. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
[TBL] [Abstract][Full Text] [Related]
17. Improvement of tumor cell depletion by combining immunomagnetic positive selection of CD34-positive hematopoietic stem cells and negative selection (purging) of tumor cells.
Hoppe B; Mohr M; Roots-Weiss A; Kienast J; Berdel WE
Bone Marrow Transplant; 1999 Apr; 23(8):809-17. PubMed ID: 10231144
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic characteristics of PB-mobilised CD34+ hematopoietic progenitor cells.
Menéndez P; del Cañizo MC; Orfao A
J Biol Regul Homeost Agents; 2001; 15(1):53-61. PubMed ID: 11388745
[No Abstract] [Full Text] [Related]
19. Genetically engineered fluorescent cell marker for labeling CD34+ hematopoietic stem cells.
Ye K; Jin S; Schultz JS
Biotechnol Prog; 2004; 20(2):561-5. PubMed ID: 15059003
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility in maximizing CD34+ cell count in stem cell grafts.
Burt RK
Stem Cells; 1999; 17(6):373-6. PubMed ID: 10606166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
